New drug trial aims to tame debilitating muscle disease
NCT ID NCT06138743
Summary
This early-stage study is testing a new drug called ARO-DM1 in adults with myotonic dystrophy type 1, a genetic disorder that causes progressive muscle weakness and stiffness. The main goal is to see if the drug is safe and how the body processes it. Researchers will also measure if it helps improve muscle function, movement, and daily activities for participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGLiverpool, New South Wales, 2170, Australia
-
Research Site
RECRUITINGBirtinya, Queensland, 4575, Australia
-
Research Site
RECRUITINGHerston, Queensland, 4029, Australia
-
Research Site
RECRUITINGMelbourne, Victoria, 3004, Australia
-
Research Site
RECRUITINGChristchurch, 8011, New Zealand
-
Research Site
RECRUITINGTaichung, 40447, Taiwan
-
Research Site
RECRUITINGTaipei, 10041, Taiwan
-
Research Site
RECRUITINGTaipei, 11217, Taiwan
-
Research Site
RECRUITINGBangkok, Bangkok, 10700, Thailand
-
Research Site
RECRUITINGHat Yai, Changwat Songkhla, 90110, Thailand
-
Research Site
RECRUITINGLampang, 52000, Thailand
Conditions
Explore the condition pages connected to this study.